Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1 (Original) A a synergistic herbal formulation as a brain tonic, cognition, recalling of thoughts and as an antioxiadant capable of treating or preventing amnesia and having property for improving memory, said formulation comprising pharmaceutically acceptable amounts of extracts from plants *Centella asiatica* and *Sesamum indicum* optionally along with pharmaceutically acceptable salt/s, carrier/s or dilutent/s.

2. (Original) A synergistic herbal formulation as claimed in claim 1, wherein *Sesamum indicum* oil is about 2 to 20 % and *Centella asiatica* oil is about 1 to 15%.

3. (Original) A synergistic herbal formulation as claimed in claim 2, wherein *Sesamum indicum* oil is about 10 % and *Centella asiatica* oil is about 5%.

4. (Original) A synergistic herbal formulation as claimed in claim 3, wherein *Sesamum indicum* oil is about 4 % and *Centella asiatica* oil is about 2%.

5. (Original) A synergistic herbal formulation as claimed in claim 1, wherein the pharmaceutically acceptable salt/s, carrier/s or dilutent/s are selected from group comprising of lactose, mannitol, sorbitol, microcrystalline cellulose, sucrose, sodium citrate, sodium chloride or dicalcium phosphate.

6. (Original) A synergistic herbal formulation as claimed in claim 1, wherein said formulation has a high antioxidant, cooling, oleaginous, diuretic and nerve relaxant properties.

7. (Original) A synergistic herbal formulation as claimed in claim 1, wherein the said formulation may be delivered in the form of capsule, tablet, syrup, suspension, pills or elixirs.

8. (Original) A synergistic herbal formulation as claimed in claim 1, wherein extract of the formulation is obtained from leaves of *Centella asiatica* and seeds of *Sesaumum indicum.*

9. (Currently Amended) A synergistic herbal formulation as claimed in ~~claims 1 and 8~~ claim 1, wherein plant parts are selected from a group consisting of seeds of white and black varieties and leaves.

10. (Original) A synergistic herbal formulation as claimed in claim 1, wherein said formulation is useful for curing migraine, vertigo, leucoderma, anaemia and improve appetite.

11. (Original) A synergistic herbal formulation as claimed in claim 1, wherein said formulation may be used for curing wounds, fractures, syphilitic skin diseases, both externally and internally and also in treatment of leprosy and to ameliorate the symptoms of disease and to improve the general health of the patient.

12. (Original) A synergistic herbal formulation as claimed in claim 1, wherein saiod formulation is useful in reducing reduce the pain of piles, stomachic, and enlargement of spleen.

13. (Original) A synergistic herbal formulation as claimed in claim 1, wherein dosage of the formulation in the range of about 20-110 mg/kg does not show abnormality of the locomotor activity, on passive avoidance test showed significant and dose dependent activity, showed significant and dose dependent antioxidant activity of the frontal cortex and of striatum regions of the brain.

14. (Original) A synergistic herbal formulation as claimed in claim 13, wherein dosage of the said formulation in the range of about 25-100 mg/kg does not show abnormality of the locomotor activity, on passive avoidance test shows significant and dose dependent activity and shows significant and dose dependent antioxidant activity of the frontal cortex and of striatum regions of the brain.

15. (Original) A synergistic herbal formulation as claimed in claim 1, wherein dosage of synergistic formulation reduces the impairment of memory acquisition by reducing the latency period in the range of about 0.05 to 2.0 seconds.

16. (Original) A synergistic herbal formulation as claimed in claim 15, wherein dosage of synergistic formulation reduces the impairment of memory acquisition by reducing the latency period in the range of about 0.18 to 1.22 seconds.

17. (Original) A synergistic herbal formulation as claimed in claim 1, wherein dosage of synergistic formulation reduces the impairment of memory acquisition by reducing number of mistakes in the range of about 1 to 35.

18. (Original) A synergistic herbal formulation as claimed in claim 17, wherein dosage of synergistic formulation reduces the impairment of memory acquisition by reducing the number of mistakes in the range of about 6.1 to 27.

19. (Original) A synergistic herbal formulation as claimed in claim 1, wherein dosage of synergistic formulation enhances the body weight in the range of about 140 to 170 gms.

20. (Original) A synergistic herbal formulation as claimed in claim 19, wherein dosage of synergistic formulation enhances the body weight in the range of about 141.6 to 168.7 gms

21. (Original) A synergistic herbal formulation as claimed in claim 1, wherein dosage of synergistic formulation enhances the kidney weight in the range of about 0.8 to 1.5 gms.

22. (Original) A synergistic herbal formulation as claimed in claim 21, wherein dosage of synergistic formulation enhances the kidney weight in the range of about 0.82 to 1.03 gms.

23. (Original) A synergistic herbal formulation as claimed in claim 1, wherein dosage of synergistic formulation enhances the liver weight in the range of about 4 to 7 gms.

24. (Original) A synergistic herbal formulation as claimed in claim 23, wherein dosage of synergistic formulation enhances the liver weight in the range of about 5.26 to 6.42 gms

25. (Original) A synergistic herbal formulation as claimed in claim 1, wherein dosage of synergistic formulation enhances the spleen weight in the range of about 0.60 to 0.80 gms.

26. (Original) A synergistic herbal formulation as claimed in claim 25, wherein dosage of synergistic formulation enhances the spleen weight in the range of about 0.63 to 0.76 gms.

27. (Original) A synergistic herbal formulation as claimed in claim 1, wherein dosage of synergistic formulation under non-stress conditions lowers the lipid peroxidase (LPO) activity in the frontal cortex and stratium regions of the brain in the range of 1.0 to 5.0.

28. (Original) A synergistic herbal formulation as claimed in claim 27, wherein dosage of synergistic formulation under non-stress conditions lower the lipid peroxidase (LPO) activity in the frontal cortex and stratium regions of the brain in the range of 0.74 to 3.48.

29. (Original) A synergistic herbal formulation as claimed in claim 1, wherein dosage of synergistic formulation under non-stress conditions enhances the catalase (CAT) activity in the frontal cortex and stratium regions of the brain in the range of 22 to 40.

30. (Original) A synergistic herbal formulation as claimed in claim 29, wherein dosage of synergistic formulation under non-stress conditions enhances the catalase (CAT) activity in the frontal cortex and stratium regions of the brain in the range of 24.5 to 35.3.

31. (Original) A synergistic herbal formulation as claimed in claim 1, wherein dosage of synergistic formulation under non-stress conditions enhances the superoxide dismutase (SOD) in the frontal cortex and stratium regions of the brain activity in the range of 22 to 40.

32. (Original) A synergistic herbal formulation as claimed in claim 31, wherein dosage of synergistic formulation non-stress conditions enhance the superoxide dismutase (SOD) activity in the frontal cortex and stratium regions of the brain in the range of 23.2. to 30.3.

33. (Original) A synergistic herbal formulation as claimed in claim 1, wherein dosage of synergistic formulation under stress conditions lower the LPO activity in the frontal cortex and stratium regions of the brain in the range of about 1 to 7.

34. (Original) A synergistic herbal formulation as claimed in claim 33, wherein dosage of synergistic formulation under stress conditions lower the LPO activity in the range of about 2.8 to 4.86.

35. (Original) A synergistic herbal formulation as claimed in claim 1, wherein dosage of synergistic formulation under chronic stress conditions enhance CAT activity in the frontal cortex and stratium regions of the brain in the range of 10 to 25.

36. (Original) A synergistic herbal formulation as claimed in claim 35, wherein dosage of synergistic formulation under chronic stress conditions enhance CAT activity in the frontal cortex and stratium regions of the brain in the range of 12.4 to 22.5.

37. (Original) A synergistic herbal formulation as claimed in claim 1, wherein dosage of synergistic formulation under chronic stress conditions lower the SOD activity in the frontal cortex and stratium regions of the brain in the range of 20 to 35.

38. (Original) A synergistic herbal formulation as claimed in claim 37, wherein dosage of synergistic formulation under chronic stress conditions lower SOD activity in the frontal cortex and stratium regions of the brain in the range of 21 to 33.

39. (Original) A method of preparing a synergistic herbal formulation as a brain tonic, cognition, recalling of thoughts and as an antioxiadant capable of treating or preventing amnesia and having property for improving memory, said method comprising steps of:

a. extracting the powdered material obtained from seeds of *Sesamum indicum* and leaves of *Centella asiatica* in aqueous alcohol,
b. filtering the extract of step (a) to remove the debris,
c. concentrating and lyophislizing the filtrate obtained from step (b) at a temperature of less than about 55°C, and
d. mixing the plant extracts obtained in step (c) with carbohydrates of about 70 % and alcohol of about 12 % to make a volume of 100 ml to obtain the formulation

40. (Original) A method as claimed in claim 39, wherein aqueous alcohol in the step (a) is about 60%.

41. (Original) A method as claimed in claim 40, wherein aqueous alcohol in the step (a) is about 50%.

42. (Original) A method as claimed in claim 39, wherein aqueous alcohol in step (a) is ethanol.

43. (Original) A method as claimed in claim 39, wherein temperature in the step (b) is about 50°C.

44. (Original) A method as claimed in claim 39, wherein carbohydrates in step (d) are selected from sucrose or lactose.

45. (Currently Amended) A method as claimed in ~~claims 39 and 44~~ claim 39, wherein carbohydrate concentration is about 66%.

46. (Original) A method as claimed in claim 39, wherein alcohol in step (d) is about 10%.

47. (Original) A method as claimed in claim 39, wherein *Sesamum indicum* oil is in the range of about 2to 20 % and *Centella asiatica* oil is in the range of about 1to 15%.

48. (Original) A method as claimed in claim 47, wherein *Sesamum indicum* oil is about 10 % and *Centella asiatica* oil is about 5%.

49. (Original) A method as claimed in claim 48, wherein *Sesamum indicum* oil is about 4 % and *Centella asiatica* oil is about 2%.

50. (Original) A method as claimed in claim 39, wherein synergistic formulation has a high antioxidant,cooling, oleaginous, diuretic and nerve relaxant properties.

51. (Original) A method as claimed in claim 39, wherein synergistic formulation may be delivered in form of capsule, tablet, syrup, suspension, pills or elixirs.

52. (Original) A method as claimed in claims 39, wherein plant parts are selected from a group consisting of seeds of white and black varieties and leaves.

53. (Original) A method treating and/or preventing amnesia and improving memory in a mammal, particulary humans said method comprsing administering synergistic herbal formulation of extracts from plants *Centella asiatica* and *Seasmum indicum* optionally along with pharamaceutically acceptable salt/s, carrier/s or dilutent/s to a subject.

54. (Original) A method as claimed in claim 53, wherein synergistic formulation is useful for curing migraine, vertigo, leucoderma, anaemia and improve appetite.

55. (Original) A method as claimed in claim 53, wherein synergistic formulation is useful for curing wounds, fractures, syphilitic skin diseases, both externally and internally and also in treatment of leprosy and to ameliorate the symptoms of disease and to improve the general health of the patient.

56. (Original) A method as claimed in claim 53, wherein synergistic formulation is useful in reducing reduce the pain of piles, stomachic, and enlargement of spleen.

57. (Original) A method as claimed in claim 53, wherein pharmaceutically acceptable salt/s, dilutent/s, carrier/s are selected from group comprising of lactose, mannitol, sorbitol, microcrystalline cellulose, sucrose, sodium citrate, sodium chloride or dicalcium phosphate.

58. (Original) A method as claimed in claim 53, wherein dosage of synergistic formulation in the range of about 20-110 mg/kg does not show abnormality of the locomotor activity, on passive avoidance test showed significant and dose dependent activity, showed significant and dose dependent antioxidant activity of the frontal cortex and of striatum regions of the brain.

59. (Original) A method as claimed in claim 58, wherein dosage of synergistic formulation in the range of about 25-100 mg/kg does not show abnormality of the locomotor activity, on passive avoidance test shows significant and dose dependent activity and shows significant and dose dependent antioxidant activity of the frontal cortex and of striatum regions of the brain.

60. (Original) A method as claimed in claim 53, wherein dosage of synergistic formulation reduces the impairment of memory acquisition by reducing the latency period in the range of about 0.05 to 2.0 seconds.

61. (Original) A method as claimed in claim 60, wherein dosage of synergistic formulation reduces the impairment of memory acquisition by reducing the latency period in the range of about 0.18 to 1.22 seconds.

62. (Original) A method as claimed in claim 53, wherein dosage of synergistic formulation reduces the impairment of memory acquisition by reducing number of mistakes in the range of about 1 to 35.

63. (Original) A method as claimed in claim 62, wherein dosage of synergistic formulation reduces the impairment of memory acquisition by reducing the number of mistakes in the range of about 6.1 to 27.

64. (Original) A method as claimed in claim 53, wherein dosage of synergistic formulation enhances the body weight in the range of about 140 to 170 gms.

65. (Original) A method as claimed in claim 64, wherein dosage of synergistic formulation enhances the body weight in the range of about 141.6 to 168.7 gms

66. (Original) A method as claimed in claim 53, wherein dosage of synergistic formulation enhances the kidney weight in the range of about 0.8 to 1.5 gms.

67. (Original) A method as claimed in claim 66, wherein dosage of synergistic formulation enhances the kidney weight in the range of about 0.82 to 1.03 gms.

68. (Original) A method as claimed in claim 53, wherein dosage of synergistic formulation enhances the liver weight in the range of about 4 to 7 gms.

69. (Original) A method as claimed in claim 68, wherein dosage of synergistic formulation enhances the liver weight in the range of about 5.26 to 6.42 gms.

70. (Original) A method as claimed in claim 53, wherein dosage of synergistic formulation enhances the spleen weight in the range of about 0.60 to 0.80 gms.

71. (Original) A method as claimed in claim 70, wherein dosage of synergistic formulation enhances the spleen weight in the range of about 0.63 to 0.76 gms.

72. (Original) A method as claimed in claim 53, wherein dosage of synergistic formulation under non-stress conditions lowers the lipid peroxidase (LPO) activity in the frontal cortex and stratium regions of the brain in the range of 1.0 to 5.0.

73. (Original) A method as claimed in claim 72, wherein dosage of synergistic formulation under non-stress conditions lower the lipid peroxidase (LPO) activity in the frontal cortex and stratium regions of the brain in the range of 0.74 to 3.48.

74. (Original) A method as claimed in claim 53, wherein dosage of synergistic formulation under non-stress conditions enhances the catalase (CAT) activity in the frontal cortex and stratium regions of the brain in the range of 22 to 40.

75. (Original) A method as claimed in claim 74, wherein dosage of synergistic formulation under non-stress conditions enhances the catalase (CAT) activity in the frontal cortex and stratium regions of the brain in the range of 24.5 to 35.3.

76. (Original) A method as claimed in claim 53, wherein dosage of synergistic formulation under non-stress conditions enhances the superoxide dismutase (SOD) in the frontal cortex and stratium regions of the brain activity in the range of 22 to 40.

77. (Original) A method as claimed in claim 76, wherein dosage of synergistic formulation non-stress conditions enhance the superoxide dismutase (SOD) activity in the frontal cortex and stratium regions of the brain in the range of 23.2. to 30.3

78. (Original) A method as claimed in claim 53, wherein dosage of synergistic formulation under stress conditions lower the LPO activity in the frontal cortex and stratium regions of the brain in the range of about 1 to 7.

79. (Original) A method as claimed in claim 78, wherein dosage of synergistic formulation under stress conditions lower the LPO activity in the range of about 2.8 to 4.86.

80. (Original) A method as claimed in claim 53, wherein dosage of synergistic formulation under chronic stress conditions enhance CAT activity in the frontal cortex and stratium regions of the brain in the range of 10 to 25.

81. (Original) A method as claimed in claim 80, wherein dosage of synergistic formulation under chronic stress conditions enhance CAT activity in the frontal cortex and stratium regions of the brain in the range of 12.4 to 22.5.

82. (Original) A method as claimed in claim 53, wherein dosage of synergistic formulation under chronic stress conditions lower the SOD activity in the frontal cortex and stratium regions of the brain in the range of 20 to 35.

83. (Original) A method as claimed in claim 82, wherein dosage of synergistic formulation under chronic stress conditions lower SOD activity in the frontal cortex and stratium regions of the brain in the range of 21 to 33.